SINT1A Study
Please note that participation in the SINT1A study is no longer possible!The SINT1A study (Supplementation with B. INfantis for Mitigation of Type 1 Diabetes Autoimmunity) is a research study for infants with an increased risk of type 1 diabetes. The aim of the study is to prevent the development of type 1 diabetes. Infants up to the age of six weeks were eligible to participate. 1149 infants were enrolled in the SINT1A study. Participation in this prevention study is no longer possible.
Type 1 diabetes is caused by the immune system mistakenly reacting to the insulin-producing cells (beta cells) in the pancreas. The beta cells are destroyed by this mistaken reaction of the immune system. The body’s own insulin is often the first target of this immune reaction, which leads to type 1 diabetes.
What is the SINT1A study?
The SINT1A study investigates whether giving the probiotic B. infantis can prevent the development of type 1 diabetes in children with an increased risk of type 1 diabetes. In the study, the probiotic is given orally (by mouth). The aim is for this to positively influence the intestinal flora and thus have a regulating effect on the immune system. In the study, our aim is to investigate whether this can reduce mistaken and pathogenic immune responses, such as those in type 1 diabetes, as well as other diseases, such as celiac disease, and thus prevent the disease.
The SINT1A study (Supplementation with B. INfantis for Mitigation of Type 1 Diabetes Autoimmunity) is a research study for infants with an increased risk of type 1 diabetes. The aim of the study is to prevent the development of type 1 diabetes. Infants up to the age of six weeks were eligible to participate. 1149 infants were enrolled in the SINT1A study. Participation in this prevention study is no longer possible.
Type 1 diabetes is caused by the immune system mistakenly reacting to the insulin-producing cells (beta cells) in the pancreas. The beta cells are destroyed by this mistaken reaction of the immune system. The body’s own insulin is often the first target of this immune reaction, which leads to type 1 diabetes.
What is the SINT1A study?
The SINT1A study investigates whether giving the probiotic B. infantis can prevent the development of type 1 diabetes in children with an increased risk of type 1 diabetes. In the study, the probiotic is given orally (by mouth). The aim is for this to positively influence the intestinal flora and thus have a regulating effect on the immune system. In the study, our aim is to investigate whether this can reduce mistaken and pathogenic immune responses, such as those in type 1 diabetes, as well as other diseases, such as celiac disease, and thus prevent the disease.
